Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the candidiasis therapeutics market right now?

The size of the candidiasis therapeutics market has consistently expanded in the past few years. The market value is set to rise from $3.19 billion in 2024 to $3.3 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.4%. This progression during the historical period is due to factors such as a rise in candidiasis cases, utilization and resistance to antibiotics, infections acquired in hospitals, changes in patterns of fungal resistance, as well as awareness and educational initiatives.

How fast Is the candidiasis therapeutics market expected to grow, and what’s its future value?

The market for therapeutics treating candidiasis is set to experience a stable expansion in the coming years. The market is projected to reach $3.83 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.8%. Key factors contributing to this predicted growth include precision medicine methodologies, worldwide antifungal stewardship efforts, rising cases of Candida Auris and global initiatives to combat antifungal resistance. Significant trends projected for this period encompass advancements in drug delivery systems, the rise of telemedicine and remote patient surveillance, emphasis on patient-centric care, combinational therapies, and collaborative research endeavors.

Get your candidiasis therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

What are the leading drivers of growth in the candidiasis therapeutics market?

As the prevalence of fungal infections rises, the candidiasis therapeutics market is anticipated to expand. Fungal diseases, which can harm the skin, mucous membranes, and internal organs in humans, are caused by many kinds of fungi. Because of their compromised immune systems and the spread of fungal infections, the susceptibility to candidiasis among these individuals is heightened. This leads to greater possibilities for manufacturers to introduce and distribute more effective antifungal drugs that are targeted at the root fungal pathogens. These drugs alleviate symptoms, avert complications, fast-track patient recovery, curtail the transmission of Candida infections in healthcare environments and facilitate improved patient prognoses. For example, the University of Minnesota relayed in January 2024, that over 3.75 million deaths per year are as a result of fungal infections, with around 2.55 million of these deaths directly linked to fungal diseases. Hence, the surging rate of fungal infections is set to escalate the development of the candidiasis therapeutics market. The growing count of clinical trials is likely to drive forward the candidiasis therapeutics market. These trials, which assess the safety and efficiency of new medical procedures, drugs or devices on humans, are pivotal to the progression of candidiasis therapeutics. They implement a systematic and comprehensive method to gauge the safety and effectiveness of potential treatments. For instance, according to ClinicalTrials.gov, a component of the National Institutes of Health (NIH), a US organization tasked with executing and promoting medical research, in 2023 there were approximately 437,533 clinical trials registered. This is in contrast to 2022 when 399,499 studies were registered across all 50 US states and 221 countries. Therefore, the rising frequency of clinical trials is propelling the growth of the candidiasis therapeutics market.

What are the key segments defining the candidiasis therapeutics market?

The candidiasis therapeutics market covered in this report is segmented –

1) By Treatment Type: Medication, Surgery, Other Treatments

2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis

3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations

4) By Patient Population: Adults, Pediatrics

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments

2) By Surgery: Surgical Debridement, Organ Removal

3) By Other Treatments: Probiotics, Home Remedies, Lifestyle Modifications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

Who are the key players steering the development of the candidiasis therapeutics market?

Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

What emerging trends are influencing the growth of the candidiasis therapeutics market?

Leading corporations in the candidiasis therapeutics arena are introducing revolutionary drugs like BREXAFEMME (ibrexafungerp tablets), aiming to decrease recurring episodes of vulvovaginal candidiasis (RVVC) in adult females. BREXAFEMME (ibrexafungerp tablets) presents an oral, non-azole remedy for vulvovaginal candidiasis (VVC) and curtailing the probability of recurrent vulvovaginal candidiasis (RVVC), also termed as chronic yeast infections. For instance, Scynexis Inc., a pharmaceutical firm based in the US, secured an approval from the US Food and Drug Administration (FDA) for BREXAFEMME (ibrexafungerp tablets) in December 2022. This approval sanctions the use of BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and to reduce the occurrence of RVVC, commonly referred to as chronic yeast infections. The action of BREXAFEMME involves inhibiting the proliferation of Candida albicans, the causative agent of VVC. Notably, it is a safe and efficient therapeutic option for vulvovaginal candidiasis (VVC). It can only be obtained through prescription, and the suggested dosage is a single 150-mg capsule orally taken once daily for a day.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13182

Which regions are most influential in expanding the candidiasis therapeutics market?

North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Metaverse In Education Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/metaverse-in-education-global-market-report

Artificial Intelligence In E-commerce Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-e-commerce-global-market-report

Smart Process Application Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/smart-process-application-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: